

21 October 2025

Botanix to present at Canaccord Drug and Device Conference in Noosa

Philadelphia and Phoenix US, 21 October 2025: Clinical dermatology company Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”) is pleased to announce that their Chief Executive Officer, Dr Howie McKibbon, will be a featured presenter today at the Canaccord Drug and Device Healthcare Conference in Noosa. Following the presentation, Dr McKibbon and US Chief Financial Officer Chris Lesovitz will participate in roundtable discussions with institutional investors attending the meeting. Canaccord Genuity will host a Botanix investor roadshow for the balance of the week.

The Company will present a subset of the attached presentation.

This ASX announcement is authorised for release by the Board.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX: BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for its lead product *Sofdra*® for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries

Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan,

the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this announcement in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.

Sofdra Important Safety Information & Indication

Indication

Sofdra (sofipironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

IMPORTANT SAFETY INFORMATION

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

Who should not use *Sofdra*?

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

What should I tell my healthcare provider before using *Sofdra*?

- **Tell your healthcare provider about all of your medical conditions**, including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, especially any anticholinergic medicines.

What are possible side effects of *Sofdra*?

Serious side effects may include:

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

The most common side effects of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

Keep *Sofdra* and all medicines out of the reach of children.

Q1 FY26 Investor Update

20 October 2025

Important Notices & Disclaimer

1. Summary information

The following notice and disclaimer applies to this investor presentation ("Presentation") and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this Presentation, you represent and warrant that you are entitled to receive this Presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it. This Presentation is dated 20 October 2025 and has been prepared by Botanix Pharmaceuticals Limited (ABN 70 009 109 755) ("Botanix" or "the Company"). The information contained in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information contained in this Presentation is a summary only and should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange ("ASX"), which are available at www.asx.com.au.

2. Not an offer

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes might have on the Company and form their own views as to what information is relevant to such decisions and made their own investigations in relation to any additional information. This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares and does not and will not form any part of any contract for the acquisition of shares. Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its securities.

3. Not investment advice

This Presentation does not constitute or contain an offer, invitation, solicitation or recommendation to subscribe for, acquire or sale of any securities in Botanix, or any other financial products or securities, in any place or jurisdiction. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the Australian Securities and Investments Commission. Persons who come into possession of this Presentation should observe any such restrictions as any non-compliance could contravene applicable securities laws.

4. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

5. Financial data

All dollar values are in Australian dollars (\$ or A\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

6. Forward-looking statements and forecasts

This Presentation contains certain "forward-looking statements" and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra*® and the market for *Sofdra*®. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Any such forward-looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility). The forward-looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation. Certain data used in this Presentation have may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. It should be read in conjunction with Botanix's other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au or at <https://botanixpharma.com/invest/>

7. Disclaimer

The Company and its related bodies corporate and each of their respective directors, agents, officers, employees and advisers expressly disclaim, to the maximum extent permitted by law, all liabilities (however caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this Presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of the Company.

This Presentation is authorised for release by the Board.



Operations:
Suite 1340, 100 Front Street
Conshohocken PA 19428

Suite 202, 2390 E Camelback Road
Phoenix AZ 85016

Corporate Office:
Suite 3, 41-47 Colin St
West Perth WA 6005

Authorised for release by the Board of Directors of Botanix

www.botanixpharma.com

Q1 FY2026 Quarterly Update Overview



Corporate Overview

- ❖ Botanix is a highly experienced dermatology-focused pharmaceutical company
- ❖ Launching *Sofdra®*, the first new chemical entity to treat primary axillary hyperhidrosis (PAH)



Q1 Commercial Highlights

- ❖ Continued TRx growth of *Sofdra*
- ❖ Quarter over quarter increase in Net Sales and Gross to Net yield
- ❖ Highly productive sales team



Q1 Financial Highlights

- ❖ Strong capital position to support growth plans and profitability
- ❖ Reduced net operating cash outflow

Corporate overview: Fast-growing dermatology pharmaceutical company with successful launch of lead product for hyperhidrosis

Dermatology Focused

Sofdra[®] is the first and only new chemical entity (sofpironium) to treat primary axillary hyperhidrosis

Innovative Platform

Fulfillment platform increases patient compliance and improves gross-to-net (GTN)

Strong Capital Position

Cash of A\$49.2m, and additional A\$15.2 million of undrawn debt capacity¹

Positioned for Growth

Sales force expansion to 50 sales professionals is complete

Botanix is led by an experienced group of dermatology executives



VINCE IPPOLITO
Executive Chairman



HOWIE MCKIBBON
Chief Executive Officer



CAREY HERBERT
Chief Legal & Compliance Officer



CHRIS LESOVITZ
Chief Financial Officer, U.S.



LEISHA MARTIN
VP, Quality, Regulatory & PV



PAUL SEABACK
Chief Technical Officer




MARTINA CARTWRIGHT
VP, Medical Affairs



>30
successful
dermatology
product
launches

*developed, secured
approval for, and
commercialized*

Primary hyperhidrosis affects twice as many patients as psoriasis and is the third largest patient category in dermatology



16.1m

PRIMARY HYPERHIDROSIS PATIENTS




7.5m

PSORIASIS PATIENTS²



Sofdra® is the first and only new chemical entity for primary axillary hyperhidrosis, providing a safe and effective treatment option

Sofdra binds selectively to M3 receptors in the sweat gland, blocks acetylcholine to inhibit sweat, and is rapidly metabolised¹



FDA-Approved Indication²

The treatment of primary axillary hyperhidrosis (PAH) in adults and pediatric patients 9 years of age and older

Efficacy²

High statistical significance across co-primary endpoints:
Patient Reported (HDSM-Ax-7) and Objective (GSP)

Safety and Tolerability²


Well-tolerated with adverse events that were mostly mild or moderate and transient; No serious TEAEs were reported

Proprietary Drug Delivery System

Applicator helps limit unwanted drug contact to hands during application and ensures consistent dosing



The Botanix Fulfilment Platform offers an innovative approach with frictionless access to *Sofdra®* for dermatologists and patients



- ✓ Seamless fulfilment
- ✓ Increase in reimbursed prescriptions
- ✓ High refill adherence rates
- ✓ Supply chain cost savings – bypassing the wholesaler
- ✓ Faster decisions due to rapid insights

Q1 FY2026: Strong *Sofdra® TRx* Growth

Quarterly Commercial Highlights:

20,418
TRx

- Total prescriptions shipped grew 50% vs Q4, driven by our fulfilment platform and productive sales team


\$7.1m
Net Sales

- Net sales increased 65% quarter over quarter

23%
Gross to Net Yield


- Gross to net yield continues to improve

Sofdra® TRx shipments grew to 20,418 in Q1 FY26



Net revenue is accelerating in step with prescription growth while gross to net yield continues to improve

Sofdra® Net Sales Over Time



Net sales grew 65% from Q4 FY25 through Q1 FY26

GTN Yield Over Time



Quarterly average GTN yield improved to 23%

Q1 FY2026: Strong Financial Fundamentals

Quarterly Financial Highlights:

\$(13.1M)
Operating Cash
Outflow

- Operating cash outflows decreased by \$15.3m to \$13.1m, driven by increased receipts from product sales alongside decreased operating and product manufacturing costs

~\$29M
Inventory Balance

- Inventory balance sufficient to support sales force expansion in Q2 FY26

\$64.4M
Available Funding

- Cash and cash equivalents of \$49.2 million
- Undrawn debt of \$15.2 million¹
- Stable cash position provides runway to support *Sofdra*® growth


Significant overall reductions due to disciplined financial approach

Cash flows from operating activities	31-Dec-24	31-Mar-25	30-Jun-25	30-Sep-25	
Receipt from Royalties	423	218	195	504	
Receipts from product sales, net of fees		326	3,836	8,271	
Payments for gross to net deductions from product sales				(2,666)	
Payments for:					
a) Product manufacturing	(11,548)	(3,434)	(11,156)	(2,171)	
b) Operating costs	(6,927)	(12,702)	(14,358)	(10,241)	
c) Staff Costs	(2,426)	(2,244)	(4,513)	(3,471)	
d) G&A	(2,169)	(2,403)	(2,401)	(1,873)	
e) Royalty Payments				(495)	
Interest received	563	327	363	402	
Interest paid			(264)	(531)	
R&D Refund	1,500				
Net GST	1	(51)	(112)		
Other non-recurring payment				(844)	
Net cash from / (used in) operating activities	\$(20,583)	\$(19,963)	\$(28,410)	\$(13,115)	
Cash flows from financing activities					
Proceeds from issues of equity securities		40,000			
Proceeds from exercise of options			21		
Transaction costs related to issues of equity securities		(2,400)			
Proceeds from borrowings		30,746			
Transaction costs related to loans and borrowings		(2,615)	(2,331)		
Dividends paid		(20)			
Other (Payment for right-of-use asset)	(116)	(132)	(137)	(108)	
Net cash from / (used in) financing activities	\$(116)	\$(132)	\$65,574	\$(2,418)	
Net increase / (decrease) in cash and cash equivalents for the period					
Cash and cash equivalents at beginning of period	\$68,672	\$48,358	\$28,080	\$64,888	
Net cash from / (used in) operating activities	(20,583)	(19,963)	(28,410)	(13,115)	
Net cash from / (used in) investing activities					
Net cash from / (used in) financing activities	(116)	(132)	65,574	(2,418)	
Effect of movement in exchange rate on cash	385	(183)	(356)	(109)	
Cash and cash equivalents at end of period	\$48,358	\$28,080	\$64,888	\$49,246	

% Change Q4 FY25 to Q1 FY26

- Product manufacturing costs dropped 81%
- Operating costs fell 29%
- Staff costs declined 23%
- G&A decreased 22%
- Net cash outflow decreased from \$28.4m to \$13.1m

Our sales force has been highly productive, generating more TRx per rep than other recent dermatology launches





Expanded high-productivity salesforce to meet *Sofdra*® demand

Feb – Jun 2025
27 Active Sales Professionals



20 Oct 2025
50 Active Sales Professionals



Interest in *Sofdra®* is high amongst dermatologists with presentations accepted at leading dermatology conferences



Fall Clinical Dermatology Conference, Oct 2025


*Leading independent dermatology
continuing medical education (CME)
meeting attracting 1,200+ attendees*




Society of Dermatology Physician Associates, Nov 2025

*Leading CME event for dermatology PAs,
combining clinical education, networking,
and updates on new therapies*

Two scientific posters accepted:



One scientific poster accepted:



Three key pillars will drive Botanix's near- and long-term value



**Strong Opportunity
for Lead Asset,
Sofdra®**



**Differentiated
Fulfilment Platform**



**Solid Foundation
for Growth and
Profitability**